WJMSC foetal stem cells

Canine and equine foetal tissue – a high-yield and readily available source of stem cells for therapy.

Technological issue

Mesenchymal stem cells are present in many tissues of mammalian organisms. At Bioceltix, the adipose tissue-derived cells are used as the active pharmaceutical ingredient of therapeutic products.

However, while adipose tissue is an efficient source of cells, it is also fairly scarce, as it is only obtained from donors during routine surgical procedures. In addition, adipose tissue donors may slightly differ in age, which in turn may cause the cells isolated for production to vary in parameters.

Our solution

At Bioceltix, we develop methods for obtaining mesenchymal stem cells from foetal tissues of dogs and horses – the umbilical cord and the placenta, both of which are rich sources of MSCs. The advantage of using foetal tissues as the starting materials for cell isolation lies in their high availability. What is more, their extraction does not require invasive surgical procedures in most cases.

Furthermore, cells obtained from foetal tissues of newborn animals are identical in terms of biological age, which reduces the variance in the parameters of in vitro cultured cells associated with differences in donor age.

The third advantage of foetal tissue is the lower risk of tissue contamination by viruses – some common viruses lack the capacity to infect foetuses and their tissues, which reduces the costs associated with virologic testing of starting materials for the production of stem cell-based biopharmaceuticals.

Literature

Cytometry A. 2018 Jan;93(1):82-92. doi: 10.1002/cyto.a.23171

The article, published in 2018, describes placental tissue as a high-yield source of mesenchymal stem cells. Placenta-derived cells are phenotypically identical to cells isolated from adult tissues while exhibiting higher potential for nerve tissue regeneration. Placenta-derived cells also produce a large number of bioactive substances of interest to regenerative medicine, including IL-6, IL-8, MCP-1 and VEGF.

https://www.ncbi.nlm.nih.gov/pubmed/28715613

 

Methods Mol Biol. 2015;1235:131-46. doi: 10.1007/978-1-4939-1785-3_12

The article, published in 2015, presents equine foetal tissue as a high-yield source of mesenchymal stem cells for use in therapies. Using the method described in the publication, it is possible to obtain more than one million stem cells from just one gram of the source tissue. Considering the weight of a single umbilical cord, a single delivery could provide the starting material for thousands of therapeutic doses of allogeneic equine stem cells.

https://www.ncbi.nlm.nih.gov/pubmed/25388392